Triplet vs. doublet drug regimens for managing multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Triplet vs. doublet drug regimens for managing multiple myeloma

Published:2017-12-21 Issue:2 Volume:19 Page:137-149
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Offidani Massimo¹,Corvatta Laura²,Gentili Silvia³

Affiliation:

1. Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy

2. UOC Medicina, Department of Medicine, Stelluti Scala Hospital, Fabriano, Italy

3. UO Ematologia, Department of Medicine, General Hospital Civitanova, Marche, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1418856

Reference102 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

2. Improved survival in multiple myeloma and the impact of novel therapies

3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

4. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

5. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan;Hematology;2024-07-03

2. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer;Journal of Medicinal Chemistry;2023-10-05

3. Current Main Topics in Multiple Myeloma;Cancers;2023-04-08

4. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice;Cancers;2023-04-05

5. Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world;Antibody Therapeutics;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3